Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
about
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in AdolescentsAtomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescentsPharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disordersA comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD)Tourette syndrome and obsessive-compulsive disorderThe management of ticsFactors affecting treatment adherence to atomoxetine in ADHD: a systematic reviewA critical appraisal of atomoxetine in the management of ADHDDuloxetine in adults with ADHD: a randomized, placebo-controlled pilot studyEuropean clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentClinical Characteristics of Children and Adolescents with a Primary Tic Disorder.Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.European guidelines on managing adverse effects of medication for ADHD.Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review.Treatment of children and adolescents with tics and Tourette syndrome.The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesAtomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvementEffectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic reviewEvidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategiesAtomoxetine: a novel treatment for child and adult ADHDA modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.Tourette syndrome: evolving concepts.Update on attention-deficit/hyperactivity disorder and tic disorders: a review of the current literature.Evidence-based assessment of compulsive skin picking, chronic tic disorders and trichotillomania in children.The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology.An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.Pediatric psychopharmacology update: psychostimulants and tics - past, present and future.Treatment of Tourette syndrome.Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.In memoriam: Donald W. Lewis, MD (1951-2012 ).The presence of comorbidity in Tourette syndrome increases the need for pharmacological treatment.Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
P2860
Q22241419-ADC78FBF-BBB3-43F6-BEC0-73E2A9B1E2C6Q24200716-93E08512-DBFA-41B4-A54C-DDF3102F926AQ24235048-8E9B2DC4-8ED6-49BB-BDA3-E93C31D0DA9DQ24631642-1D27675E-488F-4D7F-9E88-9E70E45A5E5BQ24657240-CA77DD1B-9515-4481-A3B5-7B2B2D886D57Q24658223-4131E9EA-5481-450A-9408-4BBF43FEA9F3Q26746236-6FC4D00A-5AEF-4FD6-8379-7272A516115BQ26771187-543112DE-C0E8-48EC-8E21-67F162ACE69AQ28266572-68A6B09B-64E8-495E-ACC6-342363E0EE22Q28972478-1E7DAD9B-135F-4352-9E30-1BBB5657AFA3Q33836242-7A33B50B-98AE-4413-BE87-64367615E40FQ34370417-DC1A5496-CA73-451F-B31F-5209938CD670Q34448884-3EB00238-5555-4FCC-9DF6-CD3ADC0751F6Q34524415-57D4DE63-2571-439B-9149-47DDDAD0A623Q34565872-CA7EEA4A-BAFD-41D3-8E9E-AADF8C9FC3E9Q35666363-6E5C7369-E6DF-4020-BD46-E0E01CE313B6Q35995076-B3DAF306-190C-450E-97E1-CACEF4CDA555Q36508048-3057A14E-D479-4FD2-9411-5221A9EA808CQ36648476-498504B7-984A-4875-A026-8B65EDADEBDBQ36740445-81210249-5CE0-451D-AC8D-24FD6F93D59BQ37166161-D49B6A54-8BE1-4829-AAF6-DB6D7D4C3D9CQ37171395-31AE56EC-5850-489A-A5FC-0071692EB728Q37224562-29F98217-8C93-4F6D-A55B-CD5435C88164Q37618812-D20B58E4-06BE-4466-8716-CF89736767BAQ37638740-E843CBD3-00D6-40CF-9AAB-94CAD9DAD07FQ37864240-559059B3-21D4-47AB-A6D8-0618E4346EA2Q37906361-6541FAFA-BAA5-40ED-A643-4D23CB0247D4Q38001343-4640F80D-2BE9-40FF-933A-E7C1EC43B432Q38362252-F4550D1B-9DBA-4872-91EF-147F331B82ADQ38862420-DF9CA0BD-D3BB-4563-BB48-0626B3E72145Q39097761-07B04DA3-D31A-4941-BD7F-4591185BF6B8Q39293219-EA0F162F-A919-4FDA-8D68-0013CADF8B03Q40105996-49317BE3-55E5-4108-AC60-F673364BA8CAQ41849040-600A7E76-76AB-4C7B-BF48-3F14D0A13902Q43256690-AD01CA7F-0233-4F3D-8462-5493AC266456Q44979013-FD125B47-AF55-4DC4-A338-559A2FAF5C39Q45983820-2BA4F2E3-C4E2-429A-908B-B6F3E74D7F30Q46584563-7CA0968E-D5E6-42D0-83D1-0DAB7CFD1218Q46622853-A8F12903-7797-463B-B4F8-BF6B580A8968Q46952980-E5941159-44C8-48C1-ACB3-9A40FBDEA4D3
P2860
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@ast
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@en
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@nl
type
label
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@ast
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@en
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@nl
prefLabel
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@ast
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@en
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@nl
P2093
P3181
P1433
P1476
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders
@en
P2093
B J Coffey
D K Kelsey
D L Gilbert
D R Milton
F R Sallee
G Erenberg
L L Layton
P304
P3181
P356
10.1212/01.WNL.0000188869.58300.A7
P407
P577
2005-12-27T00:00:00Z